OpenAlex
PricingAboutJobs
Log inGet started
Work

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial

HTML

Year: 2018
Type: article
Study design: Clinical Trial
Source: The Lancet Haematology
DOI: 10.1016/s2352-3026(18)30021-8
Authors: Maro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, Naveen Pemmaraju, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Michael Andreeff, Marina Konopleva, Miranda Lim, Sherry Pierce, Susan O'Brien, Yesid Alvarado, Srdan Verstovsek, William Wierda, Hagop Kantarjian, Jorge Cortes
Institutions: The University of Texas MD Anderson Cancer Center, University of California, Irvine Medical Center
Language: English

Topic: Acute Myeloid Leukemia Research
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: Grb2, antisense oligodeoxynucleotides, liposomal drug delivery, acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, ERK1/2 inhibition, MAPK signaling, dose-limiting toxicity, tyrosine kinase mutations, signal transduction
SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute
Awards: SPORE University of Texas M. D. Anderson Cancer Center-Leukemia, Cancer Center Support Grant
OpenAlex ID: W2791230356
FWCI: 3.972
Cites: 34
Cited by: 71
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security